Atezolizumab and tiragolumab study for several solid tumors
Part of Cancer, Skin clinical trials.
This Phase 2 trial tests the cancer medicines atezolizumab and tiragolumab in people with different solid tumors. It aims to see how well these drugs work and what side effects they cause in specific patient groups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a tumor that can be safely biopsied (a tissue sample taken) as part of usual care
- Your cancer has measurable signs on scans, and prior radiation spots can’t be counted as the main target
- You must be able to join the related CD8 imaging study if there are available slots
- You’re at least 18, can sign consent, and are expected to live at least 12 weeks
- Your general strength is good (ECOG 0–1) and your blood, kidney, and liver tests meet required safety levels
- You must use reliable birth control if pregnancy is possible, and you can follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a Phase 1/2 study testing how well HTL0039732 works and is tolerated in people with advanced solid tumors that have not responded to standard treatments. It may help by offering a new treatment option and learning which cancer types and body markers respond best.
This trial tests atezolizumab, a cancer immunotherapy, for people whose tumors have high mutation levels (TMB), or are “MSI-high,” or have CMMRD. It may help shrink cancer or slow its growth by boosting the immune system’s ability to recognize the tumor.
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
This trial tests two immunotherapy drugs (atezolizumab and tiragolumab) for people with advanced triple-negative breast cancer that has not responded to standard treatments. It aims to see if this combination can shrink or slow the cancer.
This trial tests a combination of two immunotherapy drugs (tiragolumab and atezolizumab) for people with advanced solid tumors that have stopped responding to standard treatments or cannot be treated with available therapies. It may be an option if your tumor has certain immune-related markers.
This Phase 2 study tests atezolizumab, an immunotherapy drug, in people with advanced, incurable solid tumors whose tumor DNA/RNA suggests they may respond. The goal is to see if the treatment works better for patients selected by these lab results.
Hear when a new Head and Neck Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.